Clinical Trial Update: A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial investigating a glutamate transporter GLT1 for bipolar disorder was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: Bipolar Disorder | Phase 2 | Status: WITHDRAWN